DK3484888T3 - Faste former af ttk-inhibitor - Google Patents

Faste former af ttk-inhibitor Download PDF

Info

Publication number
DK3484888T3
DK3484888T3 DK17830139.6T DK17830139T DK3484888T3 DK 3484888 T3 DK3484888 T3 DK 3484888T3 DK 17830139 T DK17830139 T DK 17830139T DK 3484888 T3 DK3484888 T3 DK 3484888T3
Authority
DK
Denmark
Prior art keywords
solid forms
ttk inhibitor
ttk
inhibitor
solid
Prior art date
Application number
DK17830139.6T
Other languages
English (en)
Inventor
Sze-Wan Li
Heinz W Pauls
Peter Brent Sampson
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Application granted granted Critical
Publication of DK3484888T3 publication Critical patent/DK3484888T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17830139.6T 2016-07-18 2017-07-13 Faste former af ttk-inhibitor DK3484888T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (1)

Publication Number Publication Date
DK3484888T3 true DK3484888T3 (da) 2023-05-30

Family

ID=60991755

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17830139.6T DK3484888T3 (da) 2016-07-18 2017-07-13 Faste former af ttk-inhibitor

Country Status (26)

Country Link
US (3) US10584130B2 (da)
EP (1) EP3484888B1 (da)
JP (2) JP6961675B2 (da)
KR (2) KR102537088B1 (da)
CN (2) CN109476667B (da)
AU (2) AU2017299850B2 (da)
BR (1) BR112019000813A2 (da)
CA (1) CA3030230A1 (da)
DK (1) DK3484888T3 (da)
ES (1) ES2945108T3 (da)
FI (1) FI3484888T5 (da)
HR (1) HRP20230481T1 (da)
HU (1) HUE061872T2 (da)
IL (1) IL264173A (da)
LT (1) LT3484888T (da)
MA (1) MA45691A (da)
MX (2) MX2019000744A (da)
NZ (1) NZ749844A (da)
PL (1) PL3484888T3 (da)
PT (1) PT3484888T (da)
RS (1) RS64210B1 (da)
RU (2) RU2021124795A (da)
SG (2) SG10202103332UA (da)
SI (1) SI3484888T1 (da)
TW (2) TWI745400B (da)
WO (1) WO2018014116A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3484888T5 (fi) 2016-07-18 2024-02-26 Univ Health Network Ttk:n estäjän kiinteitä muotoja

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100578227C (zh) 2001-02-21 2010-01-06 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
AU2005304784B2 (en) * 2004-11-04 2011-03-24 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
FI3484888T5 (fi) 2016-07-18 2024-02-26 Univ Health Network Ttk:n estäjän kiinteitä muotoja

Also Published As

Publication number Publication date
TWI824313B (zh) 2023-12-01
KR102537088B1 (ko) 2023-05-25
SI3484888T1 (sl) 2023-07-31
RU2019101109A (ru) 2020-08-18
SG10202103332UA (en) 2021-05-28
FI3484888T3 (fi) 2023-05-03
LT3484888T (lt) 2023-06-12
JP7263473B2 (ja) 2023-04-24
RU2021124795A (ru) 2021-09-14
WO2018014116A1 (en) 2018-01-25
TW202202507A (zh) 2022-01-16
AU2021221447A1 (en) 2021-10-07
AU2017299850B2 (en) 2021-05-27
US20190292193A1 (en) 2019-09-26
JP2022001598A (ja) 2022-01-06
MX2019000744A (es) 2019-05-02
EP3484888A1 (en) 2019-05-22
JP2019521155A (ja) 2019-07-25
RU2019101109A3 (da) 2021-02-05
TW201803876A (zh) 2018-02-01
HRP20230481T1 (hr) 2023-07-21
PL3484888T3 (pl) 2023-06-26
IL264173A (en) 2019-02-28
TWI745400B (zh) 2021-11-11
RS64210B1 (sr) 2023-06-30
EP3484888B1 (en) 2023-02-22
CA3030230A1 (en) 2018-01-25
CN115093416A (zh) 2022-09-23
CN109476667A (zh) 2019-03-15
KR20190029601A (ko) 2019-03-20
CN115093416B (zh) 2024-04-12
RU2753905C2 (ru) 2021-08-24
AU2017299850A1 (en) 2019-01-24
US10584130B2 (en) 2020-03-10
JP6961675B2 (ja) 2021-11-05
US20200270259A1 (en) 2020-08-27
PT3484888T (pt) 2023-05-26
NZ749844A (en) 2024-03-22
AU2021221447B2 (en) 2023-09-21
US20220089601A1 (en) 2022-03-24
FI3484888T5 (fi) 2024-02-26
HUE061872T2 (hu) 2023-08-28
US11878980B2 (en) 2024-01-23
ES2945108T3 (es) 2023-06-28
EP3484888A4 (en) 2020-01-08
KR20230074839A (ko) 2023-05-31
MA45691A (fr) 2019-05-22
AU2017299850A8 (en) 2019-03-21
CN109476667B (zh) 2022-06-28
US11104681B2 (en) 2021-08-31
BR112019000813A2 (pt) 2019-04-30
MX2021008658A (es) 2021-08-19
SG11201900113UA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3371171T3 (da) Inhibitorer af RET
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3377059T3 (da) Hæmmere af cxcr2
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3465098T3 (da) Detektering af objekter
DK3431475T3 (da) Faste former af en selektiv CDK4/6-hæmmer
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3442972T3 (da) Bromdomænehæmmere
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3457851T3 (da) Derivater af sobetirom
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
DK3506882T3 (da) Fremstilling af størrelseskontrollerede mikropartikler
DK3533449T3 (da) SELEKTIV HÆMMER AF EXON-20-INSERTIONsMUTANT EGFR
DK3283210T3 (da) Fremgangsmåde
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation